The effect of sulphonylurea therapy on serum total cholesterol and high density lipoprotein cholesterol.
A study was conducted on 50 cases comprising 25 patients of non-insulin dependent diabetes mellitus and 25 age and sex matched normal individuals. The diabetic state of the patients was controlled by glibenclamide, a sulphonylurea. The levels of serum total cholesterol and high density lipoprotein cholesterol were measured at the start and 15 and 30 days after glibenclamide therapy. There was a significant (p < 0.001) decrease in the levels of serum total cholesterol from initial 222.96 +/- 31.04 mg% to 218 +/- 28.99 mg% after 15 days and to 211.8 +/- 28.42 mg% after 30 days of therapy. In no case there was increase in serum total cholesterol level. There was a significant (p < 0.001) increase in the levels of serum high density lipoprotein cholesterol from initial 20.96 +/- 4.59 mg% to 21.8 +/- 4.78 mg% after 15 days to 23.72 +/- 5.07 mg% after 30 days of glibenclamide therapy and no case showed a fall in serum high density lipoprotein cholesterol level. This favourable alteration in serum total cholesterol and high density lipoprotein cholesterol was observed in patients of non-insulin dependent diabetes mellitus having ischaemic heart disease as well.
Singh
T
T
Department of Medicine, Medical College, Amritsar.
Singh
S
S
Bhullar
G S
GS
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D005260:Female; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged
D008076:Cholesterol, HDL; D002784:Cholesterol; D005905:Glyburide